From laboratory to clinic: Rationale for biologic therapy

Dermatologic Clinics

Volumn 22, Issue 4, 2004, Pages 371-377

  Mehlis, Stephanie ^a   Gordon, Kenneth B ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CYCLOSPORIN; DENILEUKIN DIFTITOX; EFALIZUMAB; ETANERCEPT; IMMUNOLOGIC FACTOR; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; MONOCLONAL ANTIBODY; PSORALEN; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 4;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE MIGRATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; REVIEW; SYSTEMIC THERAPY; T LYMPHOCYTE ACTIVATION;

BIOLOGICAL THERAPY; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MALE; PROGNOSIS; PSORIASIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 4344709636     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(03)00124-4     Document Type: Review

References (56)

1. Koo J.Y. Current consensus and update on psoriasis therapy: a perspective from the US. J Dermatol. 26:1999;723-733
2. Weinstein G.D., White G.M. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol. 28:1993;454-459
3. Soltani K., Van Scott E.J. Patterns and sequence of tissue changes in incipient and evolving lesions of psoriasis. Arch Dermatol. 106:1972;484-490
4. Nickoloff B.J. The cytokine network in psoriasis. Arch Dermatol. 127:1991;871-884
5. Nickoloff B.J. The immunologic and genetic basis of psoriasis. Arch Dermatol. 135:1999;1104-1110
6. Wrone-Smith T., Nickoloff B.J. Dermal injection of immunocytes induces psoriasis. J Clin Invest. 98:1996;1878-1887
7. Nickoloff B.J., Kunkel S.L., Burdick M., et al. Severe combined immunodeficiency mouse and human psoriatic skin chimeras: validation of a new animal model. Am J Pathol. 146:1995;580-588
8. Boyman O., Hefti H., Suter M., Nickoloff B.J., Nestle F.O. Conversion of uninvolved to involved psoriatic skin transplanted onto AAGR mice indicates intrinsic default pathway of psoriasis disease pathogenesis. J Invest Dermatol. 119:2002;302
9. Mueller W., Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 301:1979;555
10. Ellis C.N., Gorsulowsky D.C., Hamilton T.A., et al. Cyclosporine improves psoriasis in a double-blind study. JAMA. 256:1986;3110-3116
11. Krueger J.G., Wolfe J.T., Nabeya R.T., et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med. 182:1995;2057-2068
12. Eedy D.J., Burrows D., Bridges J.M., et al. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ. 300:1990;908
13. Gardembas-Pain M., Ifrah N., Foussard C., et al. Psoriasis after allogeneic bone marrow transplantation. Arch Dermatol. 126:1990;1523
14. McInnes I.B. Rheumatoid arthritis: from bench to bedside. Rheum Dis Clin North Am. 27:2001;373-387
15. Baker B.S., Fry L. The immunology of psoriasis. Br J Dermatol. 126:1992;1-9
16. Austin L.M., Ozawa M., Kikuchi T., et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 113:1999;752-759
17. Schlaak J.F., Buslau M., Jochum W., et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 102:1994;145-149
18. Trowsdale J., Powis S.H. The MHC: relationship between linkage and function. Curr Opin Genet Dev. 2:1992;492-497
19. Berridge M.J. Lymphocyte activation in health and disease. Crit Rev Immunol. 17:1997;155-178
20. Fraser J.D., Newton M.E., Weiss A. CD28 and T cell antigen receptor signal transduction coordinately regulate interleukin 2 gene expression in response to superantigen stimulation. J Exp Med. 175:1992;1131-1134
21. Smith K.A. Interleukin-2: inception, impact, and implications. Science. 240:1988;1169-1176
22. Aringer M. T lymphocyte activation: an inside overview. Acta Med Austriaca. 29:2002;7-13
23. Friedl P., Gunzer M. Interaction of T cells with APCs: the serial encounter model. Trends Immunol. 22:2001;187-191
24. Hudrisier D., Bongrand P. Intercellular transfer of antigen-presenting cell determinants onto T cells: molecular mechanisms and biological significance. FASEB J. 16:2002;477-486
25. Fuhlbrigge R.C., Kieffer J.D., Armerding D., et al. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature. 389:1997;978-981
26. Picker L.J., Kishimoto T.K., Smith C.W., et al. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature. 349:1991;796-799
27. Groves R.W., Ross E., Barker J.N., et al. Effect of in vivo interleukin-1 on adhesion molecule expression in normal human skin. J Invest Dermatol. 98:1992;384-387
28. Robert C., Kupper T.S. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med. 341:1999;1817-1828
29. Borish L.C., Steinke J.W. 2. Cytokines and chemokines. J Allergy Clin Immunol. 111:2003;S460-S475
30. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 46:2002;1-23
31. Rottman J.B., Smith T.L., Ganley K.G., et al. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest. 81:2001;335-347
32. Gillitzer R., Ritter U., Spandau U., et al. Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol. 107:1996;778-782
33. Detmar M., Yeo K.T., Nagy J.A., et al. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol. 105:1995;44-50
34. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Biotechnology. 24:1975;524-526
35. Reichert J.M. Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr Opin Mol Ther. 4:2002;110-118
36. Mehlis S.L., Gordon K.B. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 49:2003;S44-S50
37. Singri P., West D.P., Gordon K.B. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol. 138:2002;657-663
38. Williams D.P., Parker K., Bacha P., et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng. 1:1987;493-498
39. Waters C.A., Snider C.E., Itoh K., et al. DAB486IL-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor-bearing human peripheral blood mononuclear cells. Ann N Y Acad Sci. 636:1991;403-405
40. Bagel J., Garland W.T., Breneman D., et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol. 38:1998;938-944
41. Gottlieb S.L., Gilleaudeau P., Johnson R., et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1:1995;442-447
42. Ellis C.N., Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 345:2001;248-255
43. Krueger G.G. Selective targeting of T cell subsets: focus on alefacept, a remitive therapy for psoriasis. Expert Opin Biol Ther. 2:2002;431-441
44. Leonardi C.L. Efalizumab: an overview. J Am Acad Dermatol. 49:2003;S98-S104
45. Werther W.A., Gonzalez T.N., O'Connor S.J., et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol. 157:1996;4986-4995
46. Krueger J., Gottlieb A., Miller B., et al. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol. 115:2000;333
47. Asadullah K., Docke W.D., Ebeling M., et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol. 135:1999;187-192
48. Trepicchio W.L., Ozawa M., Walters I.B., et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest. 104:1999;1527-1537
49. Goffe B., Cather J.C. Etanercept: an overview. J Am Acad Dermatol. 49:2003;S105-S111
50. Gottlieb A.B. Infliximab for psoriasis. J Am Acad Dermatol. 49:2003;S112-S117
51. Biasi D., Carletto A., Caramaschi P., et al. Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis. Inflammation. 22:1998;533-543
52. Detmar M., Brown L.F., Schon M.P., et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol. 111:1998;1-6
53. Duan H., Koga T., Kohda F., et al. Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci. 26:2001;119-124
54. Keystone E.C. Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 27:2001;427-443
55. Wakefield P.E., James W.D., Samlaska C.P., et al. Tumor necrosis factor. J Am Acad Dermatol. 24:1991;675-685
56. Yu Y., Tang L., Wang J., et al. Psoriatic lesional keratinocytes promote the maturation of human monocyte-derived Langerhans cells. Dermatology. 204:2002;94-99